TROPI

PharmaJet Tropis Intradermal Delivery System is Now Authorized for Two Nucleic Acid Vaccines

Retrieved on: 
星期三, 六月 28, 2023
Biotechnology, Health, General Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Genetics, Science, COVID-19, Clinical Trials, Injection, DNA, Human, Omicron, Use, Therapy, COVID-19 vaccine, Multimedia, Temperature, Infection, Messenger, Trial of the century, TROPI, Cervical cancer, Data, Melanoma, HPV, ZyCoV-D, Leukemia, Vaccine, Orthohantavirus

PharmaJet ®, a company engineering precision delivery systems that overcome challenges of nucleic acid vaccine delivery, today announced that its Tropis® System is now the exclusive intradermal delivery system for two authorized novel Covid-19 vaccines:

Key Points: 
  • PharmaJet ®, a company engineering precision delivery systems that overcome challenges of nucleic acid vaccine delivery, today announced that its Tropis® System is now the exclusive intradermal delivery system for two authorized novel Covid-19 vaccines:
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230628015647/en/
    PharmaJet Tropis is now the exclusive intradermal delivery system for two novel Covid-19 vaccines in India.
  • It has been used for millions of injections in multiple immunization campaigns worldwide.
  • Tropis ID has already been used for millions of injections in multiple immunization campaigns worldwide.

PharmaJet, Nigeria's National Primary Health Care Development Agency and Health-focused Consortium Launch Assessment of the PharmaJet Tropis Vaccine Delivery System

Retrieved on: 
星期二, 三月 7, 2023
Medical Supplies, Health, Medical Devices, Infectious Diseases, Research, Science, Biotechnology, Child, Immunization, Polio vaccine, ID, USAID, PATH, Jhpiego, Vaccine hesitancy, IPV, Injection, GPEI, United, Use, International development, Needle, Multimedia, Caregiver, WHO, Global Polio Eradication Initiative, Vaccine, TROPI

PharmaJet and co-investigators from the National Primary Health Care Development Agency (NPHCDA), Jhpiego , PATH and the Sydani Group met in Lagos Nigeria and have finalized the study design, outlined the timelines, protocol, and tools for the study.

Key Points: 
  • PharmaJet and co-investigators from the National Primary Health Care Development Agency (NPHCDA), Jhpiego , PATH and the Sydani Group met in Lagos Nigeria and have finalized the study design, outlined the timelines, protocol, and tools for the study.
  • It will assess the health impact, cost, and feedback from providers and caregivers of using Tropis for ID delivery of inactivated poliovirus vaccine (IPV) compared to standard intramuscular delivery using needle and syringe.
  • The PharmaJet Tropis NFIS is a WHO prequalified, hand-held device that delivers precise ID injections without needles.
  • “We are thrilled to be working with NPHCDA, Jhpiego, PATH, and Sydani on this study,” noted Paul LaBarre, Vice President of Global Business Development, PharmaJet.

Review Highlights Growing Evidence That PharmaJet’s Precision Delivery Devices Improve Nucleic Acid Vaccine Performance

Retrieved on: 
星期四, 二月 23, 2023
Biotechnology, Pharmaceutical, Health, Medical Devices, Stratis, Tissue, Safety, HIV, Orthohantavirus, University of Cape Town, Vaccine (journal), DNA, University, Antigen, Bureau of Oceans and International Environmental and Scientific Affairs, Molecular medicine, Injection, Infection, Cell, Use, MDPI, Trial of the century, Subcutaneous tissue, TROPI, Therapy, Probability, Human, Drugs Controller General of India, Multimedia, Messenger, Vaccine, COVID-19, RNA

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    The COVID-19 pandemic increased visibility of nucleic acid vaccines, such as messenger RNA (mRNA), that provide scalability and can be quickly adapted as new variants appear.
  • Historical limitations can be addressed with new administration technologies such as modern needle-free precision delivery systems.
  • “We currently have eighty-three studies ongoing with novel pharmaceuticals focusing on nucleic acid technology in addition to other new vaccine technology platforms.
  • We believe that our precision delivery devices have the potential to increase the performance and therefore probability of regulatory success of many of these candidate vaccines.”
    Refer to Instructions for Use to ensure safe injections and to review risks.

PharmaJet Presents Latest Research Showing Benefits of Needle-free at mRNA-Based Therapeutics Summit

Retrieved on: 
星期二, 七月 19, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Medical Devices, Infectious Diseases, Stratis, N/S, Research, Public health, LNP, University, Rabies, USAMRIID, Method, LinkedIn, RNA transfection, WHO, Infection, Injection, Safety, DVM, Therapy, Review, System, Lancet, Rabbit, United States Army Medical Research Institute of Infectious Diseases, Certification, Use, Sue VandeWoude, Smallpox, Vaccination, Nucleic acid, COVID-19, ID, PQS, CE marking, Veni, vidi, vici, Doctor of Philosophy, IM, U.S. FDA, Vaccine, TROPI

PharmaJet , a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the mRNA-Based Therapeutics Summit on July 27, 2022.

Key Points: 
  • PharmaJet , a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the mRNA-Based Therapeutics Summit on July 27, 2022.
  • The presentation, entitled Advances in mRNA vaccines and therapeutics delivery with PharmaJet Needle-free Injection Systems, will be presented by Carmen Ledesma-Feliciano, DVM, PhD, DACLAM, Clinical Device Specialist at PharmaJet.
  • PharmaJet Needle-free Injection Systems (NFIS) are increasingly being incorporated into preclinical and clinical studies across multiple nucleic acid vaccine and therapeutic development programs.
  • This presentationwill highlight several partner studies that show the benefits of the PharmaJet NFIS including improved immunogenicity, dose-reduction, lower cost, and better patient and healthcare worker experience.

Flora Growth Appoints Award-Winning Operations Expert Joël Reyes as SVP of Global Operations

Retrieved on: 
星期四, 一月 27, 2022
Alternative Medicine, Health, Natural Resources, Other Natural Resources, Nature, Growth, Global Operations, Forward-looking statement, Consumer Technology Association, Cosmetics, Research, Reyes, Technology, Sale, Senior, Food, Leadership, Cannabis, NASDAQ, CTA, Company, Environment, Goal, Innovation, TROPI, SVP, FLGC, CEO, Terminology, Management, Drug, Risk management

Flora Growth Corp. (NASDAQ: FLGC) (Flora'' or the Company), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, announced today the appointment of operations and personnel development expert, Jol Reyes as Senior Vice President of Global Operations.

Key Points: 
  • Flora Growth Corp. (NASDAQ: FLGC) (Flora'' or the Company), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, announced today the appointment of operations and personnel development expert, Jol Reyes as Senior Vice President of Global Operations.
  • Mr. Reyes brings extensive experience in operations management and optimization, leadership and C-suite consultation and development, business development, and strategic consultative sales, both within startups and large corporations.
  • The appointment of the SVP of Global Operations role comes as Flora Growth expands its global reach via recent acquisitions and partnerships, including: Hoshi International, which provided Flora with a pathway to European distribution and Vessel Brand Inc., which offered the Company a cannabis accessories company with a foothold in the North American cannabis market.
  • Flora Growth is well-positioned for rapid revenue growth after strategically building a house of brands and global pipeline for the sale of cannabis derivatives in 2021, Reyes said.

Flora Growth Reports H1 2021 Financial Results and Provides Guidance for H2 Revenue Anticipated Between US$9-11M

Retrieved on: 
星期四, 八月 19, 2021
Textiles, Manufacturing, Alternative Medicine, Food, Beverage, Health, Cosmetics, Retail, Agriculture, Natural Resources, Union, Industry, Company, Webcast, Ernst Loosen, Nasdaq, Koch, Access to Cannabis for Medical Purposes Regulations, Growth, Kalaya, City, Traction, Science, Tobacco, FLGC, SEC, Letter, European Union, TROPI, Central, CPG, Cosmetics, Heimat, Colombians, Â, Marketing, Awareness, IPO, NASDAQ, OTC, Food, Cannabis, Partnership, CEO, Sale, Ã, Intention, Exercise, Drug, Security (finance), Fine chemical, Management, Animal

Flora Growth Corp. (NASDAQ:FLGC) (Flora, Flora Growth, or the Company), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, is pleased to report selected financial and operating results for the six-month period ending June 30, 2021 (all amounts expressed in US dollars, unless otherwise stated).

Key Points: 
  • Flora Growth Corp. (NASDAQ:FLGC) (Flora, Flora Growth, or the Company), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, is pleased to report selected financial and operating results for the six-month period ending June 30, 2021 (all amounts expressed in US dollars, unless otherwise stated).
  • Flora Growth generated revenues of +$2M with a gross profit of 60% (unaudited), as compared to revenues of ~$100K for 2020.
  • Flora Growth is a foreign private issuer and is required to submit financial results on a half-year basis, with a 6-month window to file the unaudited results.
  • Following the presentation, Flora will offer analysts, media, and investors the opportunity to ask questions in a question-and-answer session.

 Flora Growth Expands its Food and Beverage Division, Signs Sales Agreement with Largest Colombian Distributor Representing Up to US$10 Million in Expected Annual Sales  

Retrieved on: 
星期一, 七月 12, 2021
Retail, Alternative medicine, Health, Food, Beverage, Business, Articles, Business process, Distribution, Sales, E-commerce, Kasa, Economy, Tropi, Flora Growth Corp., TROPI, FLORA GROWTH CORP.

(Kasa) has signed an initial one-year sales agreement with Importaciones y Asesorias Tropi S.A.S.

Key Points: 
  • (Kasa) has signed an initial one-year sales agreement with Importaciones y Asesorias Tropi S.A.S.
  • Kasa intends on leveraging this initial sales agreement with Colombias largest CPG distributor to generate additional sales of its entire product portfolio.
  • We believe that this sales agreement is a significant milestone for Kasa.
  • By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive.